Terumo Aortic Global Endovascular Registry
Key facts
- Where
- Amsterdam, Arnhem, Enschede, Groningen, Nieuwegein, Rotterdam, and Utrecht, NetherlandsSee the 7 sites
Where in Netherlands
- VUMC AmsterdamAmsterdam, NetherlandsContact: A.w.J HoksbergenTaking people
- Rijnstate ArnhamArnhem, NetherlandsContact: M.M.P.J ReihnenTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsContact: R.H GeelkerkenTaking people
- UMC GronigenGroningen, NetherlandsContact: Clark ZeebregtsTaking people
- St. Antonius ZiekenhuisNieuwegein, NetherlandsContact: Study CoordinatorNot yet recruiting
- Erasmus University Medical CenterRotterdam, NetherlandsContact: Hence Verhagen, Prof (principal investigator)Taking people
- DiakonessenhuisUtrecht, NetherlandsContact: Mattijs De Vries, ProfTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Vascutek Ltd.
- Trial code
- NCT04246463
- Record updated
- 13 March 2026
- Original description
Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.Read full original descriptionShow less
A Global Post Market Evaluation of Terumo Aortic Endovascular Grafts
Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.
Inclusion: Minimum age as per local regulations; Indication for aortic endovascular repair with an approved or CE marked by a Regulatory body or custom-made Terumo Aortic Endovascular graft; Ability to provide informed consent; o Emergent cases (typically younger patients with traumatic injuries) are not excluded if there is IRB/EC agreement to allow consent after intervention (i.e. consent to study participation, not to treatment) or use of a Legally Authorized Representative (LAR); Willingness to comply with the registry protocol; Willingness to adhere to follow-up visits Note: Patients currently enrolled and actively participating within the TREO registry (IP-0020-16) can have their data migrated from TREO to the TiGER registry where local EC approval has been obtained and the patient has been reconsented to TiGER for longer follow-up.
Exclusion: Patient is unable or unwilling to comply with the study follow-up regime. Patient is contraindicated per the IFU, or has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving treatment as well as the procedures and evaluations pre and post procedure.